Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.

CONCLUSIONS:: The preoperative platelet-to-lymphocyte ratio may be a promising and convenient prognostic biomarker for patients gastric cancer receiving S-1 plus oxaliplatin or oxaliplatin and capecitabine regimen neoadjuvant chemotherapy. It may be useful to help the doctors identify the high-risk patients for taking efficient treatment strategy decisions.
PMID: 30760114 [PubMed - in process]

Source: Technology in Cancer Research and Treatment - January 1, 2019 Category: Cancer & Oncology Authors: Chen L, Hao Y, Cong X, Zou M, Li S, Zhu L, Song H, Xue Y Tags: Technol Cancer Res Treat Source Type: research